Tariffs 'Threaten Global Medicine Supply': Swiss Pharma Agency
-
Italiano
it
Interpharma:“a rischio l'approvvigionamento globale dei pazienti”
Original
Read more: Interpharma:“a rischio l'approvvigionamento globale dei pazienti
+Get the most important news from Switzerland in your inbox
Customs barriers disrupt production and supply chains and hinder research and development, Interpharma told AWP. They also threaten to permanently damage the close and important economic cooperation between Switzerland and the US.
+ How pharma became Switzerland's Achilles heel in the US
The association hopes bilateral talks can continue to either reduce or exempt tariffs on drugs.
However, the announcement is a“wake-up call”, says Interpharma. Trump's plan hits Switzerland's most important export sector, which is crucial not only for prosperity, but also for tax revenues and research. In 2024 alone, the branch exported medicines worth more than CHF100 billion.
+ Sandoz board chair 'convinced that common sense will ultimately prevail' on US pharma tariffs
The association urged Swiss politicians to quickly send visible signals to ensure international competitiveness. These include the suspension of new regulatory projects and the modernisation of the pricing mechanism for innovative therapies.
In the medium term, a comprehensive life sciences strategy is also deemed necessary, to be developed jointly by the federal administration, politics and industry. Without a clear focus on the role of the pharmaceutical industry in the economy and healthcare, the existing obstacles will remain.
“Continuing as before is not an option,” said Interpharma. Only with constructive solutions is it possible to maintain the pharmaceutical industry as an engine of growth, the association concludes.
More More Global trade Switzerland braces for 100% US medicine tariffThis content was published on Sep 26, 2025 Switzerland braces for impact of US 100% pharmaceutical tariff.
Read more: Switzerland braces for 100% US medicine tarifTranslated from Italian with DeepL/mga

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Kintsu Launches Shype On Hyperliquid
- Barunson, Studio Behind Parasite, To Launch Nplug IP Remixing Platform On Story And Bring Flagship IP Onchain
- Moonbirds And Azuki IP Coming To Verse8 As AI-Native Game Platform Integrates With Story
- Leverage Shares Launches First 3X Single-Stock Etps On HOOD, HIMS, UNH And Others
- Alchemy Markets Launches Tradingview Integration For Direct Chart-Based Trading
- Dexari Unveils $1M Cash Prize Trading Competition
Comments
No comment